


**Supplemental Figure 1**




**Supplemental Figure 1:** Average (±SD) delivery time in air versus average delivery time in vivo for all injections per viscosity: SFHIGH 27G STW and UTW (top), SFLOW 27G STW, SFHIGH 29G TW (bottom) device configurations. Dotted red line represents nominal 15 second injection duration. G = gauge; SFLOW = Low Spring Force; SFHIGH = High Spring Force; TW = thin wall; STW = special thin wall; UTW = ultra-thin wall.

**Supplemental Figure 2**



**Supplemental Figure 2:** A single injection case (SFHigh 27G STW, 5 cP) which showed predominant SC deposition with an observation of nominal intradermal injectate (blue circle). CP = centipoise; G = gauge; SC = subcutaneous; SFHIGH = High Spring Force; STW = special thin wall.

**Supplemental Figure 3**



**Supplemental Figure 3:** Observed erythema (left) and wheal (right) scores (0-4) by viscosity over time expressed as a percentage of total injections for LVAI SFLOW 27G STW (top) and SFHIGH 29G TW device configurations (bottom) immediately after injection (T0) and through resolution by viscosity. Regardless of injection test condition, all erythema resolved to non-detectable levels (Score=0; dark green) by T-60 minutes (T1) post-injection; all wheal scores resolved within 2 hours (T2) post injection. G = gauge; LVAI = large volume autoinjector; SFLOW = Low Spring Force; SFHIGH = High Spring Force; TW = thin wall; STW = special thin wall; UTW = ultra-thin wall.